PT  - JOURNAL ARTICLE
AU  - Goldberg, David S
AU  - Tewksbury, Erin
AU  - Wadsworth, Matthew
TI  - Procurement of Pancreatic Islet Cells from Deceased Donors: Updated Data and Gaps in Reporting
AID  - 10.1101/2025.02.21.25322017
DP  - 2025 Jan 01
TA  - medRxiv
PG  - 2025.02.21.25322017
4099  - http://medrxiv.org/content/early/2025/02/25/2025.02.21.25322017.short
4100  - http://medrxiv.org/content/early/2025/02/25/2025.02.21.25322017.full
AB  - In 2020, CMS updated the ‘Final Rule’ for organ procurement organizations (OPO) in 2020 to include new metrics of OPO performance with a carveout whereby pancreata procured for research count as a “donor” to reward OPOs procuring pancreata for islet cell research or transplantation. Yet data suggested OPOs took advantage of this loophole, leading to updated guidance in 2024 to require OPOs classify whether procured research pancreata were “accepted for islet cell research.” Based on updated data using the new CMS codes, the increase in research pancreas procurement was nearly half previously reported, but far greater than prior to 2020. Importantly, the number of pancreata OPOs reported were accepted for islet cell research were an order of magnitude greater than what was used by the Integrated Islet Cell Distribution Program (IIDP) and the Network for Pancreatic Organ Donors with Diabetes (nPOD), the two largest sources of islet cell/pancreata for qualified researchers in the US. Inappropriate procurement of organs, and mislabeling them as being used for “islet cell research” raises questions of fraud, waste, and abuse that requires further investigation and transprancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study uses publicly available data, by request, from the OPTN and frm the IIDP website (https://iidp.coh.org/Overview/Program-Statistics)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe OPTN data are available by request from the OPTN, which were made available in aggregate data per OPO per year, and due to the DUA require other investigators request the data from the OPTN. the IIDP data are available on the IIDP website: https://iidp.coh.org/Overview/Program-Statistics https://iidp.coh.org/Overview/Program-Statistics (CMS)Centers for Medicare and Medicaid Services(OPOs)Organ procurement organizations(OPTN)Organ Procurement and Transplantation Network(IIDP)Integrated Islet Cell Distribution Program(nPOD)Network for Pancreatic Organ Donors with Diabetes